Medetomidine/vatinoxan

Medetomidine/vatinoxan, sold under the brand name Zenalpha, is a veterinary fixed dose combination medication used as a sedative and analgesic for dogs.[1][2] It contains medetomidine, an alpha2-adrenoceptor agonist, as the hydrochloride; and vatinoxan, an alpha2-adrenoceptor antagonist, as the hydrochloride.[2][3]

Medetomidine/vatinoxan
Chemical structures of medetomidine (top) and vatinoxan
Combination of
Medetomidinealpha2-adrenoceptor agonist
Vatinoxanalpha2-adrenoceptor antagonist
Clinical data
Trade namesZenalpha
License data
Routes of
administration
Intramuscular
ATC code
  • None
Legal status
Legal status

It was approved for veterinary use in the United States in May 2022,[2] and in Canada in May 2023.[1]

References

edit
  1. ^ a b c "Notice: Multiple additions to the Prescription Drug List (PDL) [2023-06-23]". Health Canada. 23 June 2023. Retrieved 3 March 2024.
  2. ^ a b c d "Zenalpha- vatinoxan hydrochloride and medetomidine hydrochloride solution". DailyMed. 11 May 2022. Retrieved 3 March 2024.
  3. ^ "Zenalpha – Label" (PDF). Dechra Veterinary Products Inc. Government of Canada. 20 March 2023.